CMBA
HRTX icon

C.M. Bidwell & Associates’s Heron Therapeutics HRTX Stock Holding History

C.M. Bidwell & Associates’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-291
Closed -$3K – 571
2021
Q4 		$3K Hold
291
– – ﹤0.01% 489
2021
Q3 		$3K Hold
291
– – ﹤0.01% 504
2021
Q2 		$5K Buy
+291
New +$4.63K ﹤0.01% 456

Other funds holding HRTX

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return

C.M. Bidwell & Associates's HRTX Position: Q1 2022 in Review

C.M. Bidwell & Associates sold out of Heron Therapeutics (HRTX) in Q1 2022, closing a stake of 291 shares — an estimated $3K sold.

C.M. Bidwell & Associates first reported a position in HRTX in Q2 2021 and held it in 3 quarters. The position peaked at $5K in Q2 2021. 186 funds tracked by Wall St. Rank hold HRTX as of Q1 2022.

  • C.M. Bidwell & Associates reported no remaining Heron Therapeutics position as of Q1 2022 after selling out during the quarter.
  • C.M. Bidwell & Associates sold 291 Heron Therapeutics shares in Q1 2022, an estimated $3K.
  • C.M. Bidwell & Associates first reported a position in Heron Therapeutics in Q2 2021 and held it in 3 quarters.
  • C.M. Bidwell & Associates's Heron Therapeutics position peaked at $5K in Q2 2021.
  • 186 funds tracked by Wall St. Rank held Heron Therapeutics as of Q1 2022.

Based on C.M. Bidwell & Associates's 13F filing for Q1 2022, filed 29 Apr 2022.